(REGN) Regeneron Pharmaceuticals, Inc. Company Overview

Regeneron Pharmaceuticals, Inc. is a biotechnology company listed on the Nasdaq Global Select Market under the ticker REGN. It discovers, develops, manufactures, and commercializes medicines, particularly antibody-based therapies. Its portfolio covers retinal disease, inflammation, oncology, cardiovascular and metabolic disorders, rare diseases, infectious disease, and hematology. Discovery science, clinical development, manufacturing, and much of commercialization remain connected inside one operating system rather than being assembled mainly through acquisitions.

Regeneron is a research platform that has become a commercial portfolio. EYLEA HD and EYLEA address retinal diseases; Dupixent is a multi-indication immunology franchise marketed with Sanofi; Libtayo is an oncology medicine; and Praluent, Evkeeza, Kevzara, and newer launches add smaller but strategically important revenue streams. The Regeneron Genetics Center and proprietary platforms help identify targets and generate fully human antibodies. The official technology overview explains how the VelociSuite platforms connect target discovery, validation, and antibody creation.

How should researchers classify the business?

Regeneron has three principal revenue channels. First, it records net product sales for medicines it commercializes directly, led by the U.S. EYLEA franchise and U.S. sales of Libtayo, Praluent, Evkeeza, and newer products. Second, it records collaboration revenue, including its share of profits from Sanofi-marketed products such as Dupixent and from Bayer-marketed EYLEA outside the United States. Third, it records other revenue, including reimbursements, technology-related amounts, and other contractual income. This mix means reported revenue is not identical to worldwide end-market sales: some of Regeneron’s most valuable products are recorded by partners, while Regeneron recognizes a contractual share of the economics.

Which revenue stream is largest in the latest quarter?

Product-level growth can therefore diverge from reported company growth. In Q1 2026, Sanofi collaboration revenue rose to $1.605 billion, while Bayer collaboration revenue fell to $287 million. Net product sales reached $1.535 billion. The official Q1 2026 earnings release provides the latest product and collaboration detail.

Dupixent is the largest global end-market franchise associated with Regeneron, although Sanofi records the product’s worldwide sales and Regeneron recognizes collaboration revenue. Global Dupixent sales were $4.880 billion in Q1 2026, up 33% year over year. The combined global EYLEA HD and EYLEA franchise generated $1.670 billion, down 12%, as newer EYLEA HD growth only partly offset erosion in the older formulation. Libtayo reached $438 million globally, up 54%, making oncology the clearest emerging commercial diversification engine.

What is the central product-mix tension?

The transition from EYLEA to EYLEA HD is strategically important because the older product lost U.S. regulatory exclusivity in May 2024 and now faces biosimilars and competing retinal therapies. In FY2025, combined U.S. EYLEA HD and EYLEA sales were $4.385 billion, equal to 31% of Regeneron revenue, down from 42% in FY2024. EYLEA HD represented 37% of the combined U.S. franchise in FY2025. That makes conversion speed, dosing differentiation, physician demand, net pricing, and biosimilar timing more informative than a single headline sales number.

How broad is the pipeline behind the marketed portfolio?

The 2026 proxy describes nearly 50 clinical candidates, while the official investigational pipeline shows programs across ophthalmology, immunology, oncology, hematology, rare disease, obesity, and other fields. Pipeline breadth reduces single-asset dependence but not binary risk: failures, safety findings, or weak differentiation can erase an individual program’s value.

For the quarter ended March 31, 2026, revenue increased 19% to $3.605 billion. GAAP net income declined 10% to $727 million and GAAP diluted EPS declined 7% to $6.75, while non-GAAP net income rose 12% to $1.040 billion and non-GAAP diluted EPS rose 15% to $9.47. The gap includes acquired in-process research and development, stock-based compensation, and other adjustments. GAAP shows the full accounting burden, while the adjusted view highlights operating momentum before selected charges.

Why did margins move differently from revenue?

GAAP R&D expense increased 16% to $1.544 billion, acquired IPR&D reached $102 million, and cost of goods sold increased 40% to $373 million. Gross margin on net product sales declined to 76% from 81%, partly because of a temporary production interruption at the Limerick facility. Management said initial production resumed in Q2 2026 and expected normalization by the end of the quarter without affecting product availability. The Q1 2026 Form 10-Q provides the underlying statements and risk disclosures.

Regeneron’s history matters because it explains both its scientific culture and its tolerance for long-duration investment. The company’s 2026 proxy notes that it took more than 20 years to obtain its first product approval and nearly 25 years to become profitable. That path encouraged an internal platform model: build reusable scientific and manufacturing capabilities, then apply them repeatedly across diseases. The official company history documents the turning points behind today’s structure.

1. 1988
   Regeneron was founded around a science-led model. Founder Leonard Schleifer and scientist George Yancopoulos still shape strategy and governance.
2. 1991–1993
   The IPO raised $91.6 million, followed by the acquisition of a manufacturing facility before any product approval. Owning capacity became a long-term strategic asset, but also raised fixed-cost exposure.
3. 1997
   A major Phase 3 failure forced the company to regroup. The lesson still applies: platform quality cannot remove clinical outcome risk.
4. 2003–2007
   VelociGene research was published, and collaborations with Bayer and Sanofi created global development and commercialization leverage.
5. 2011
   EYLEA received U.S. approval, transforming Regeneron from a research story into a scaled commercial biotechnology company.
6. 2014–2018
   The Regeneron Genetics Center launched; Dupixent and Libtayo expanded the company into immunology and oncology, diversifying the therapeutic base.
7. 2023
   EYLEA HD was approved and Regeneron acquired Decibel Therapeutics, reinforcing both lifecycle management and expansion into genetic medicine.

What did the collaboration strategy change?

Sanofi and Bayer reduced the capital and commercial burden of building a worldwide sales infrastructure for every program. In exchange, Regeneron shares economics and depends on partner execution, reporting, launch sequencing, and cost allocation. The model combines direct ownership in selected markets with profit-sharing elsewhere, improving reach while making contract structure important to financial analysis.

The moat is best understood as a system of complementary assets rather than a single patent. Proprietary discovery technology can generate candidates; human genetics can improve target selection; internal clinical and regulatory teams can advance programs; owned manufacturing can support biologics supply; and established commercial relationships can scale successful medicines. Each element is expensive to reproduce, and the value rises when the elements work together.

Which resources are hardest for competitors to copy?

The scorecard is an analytical interpretation, not a credit rating. It highlights the trade-off: Regeneron has unusually deep science and financial resources, but current earnings still depend heavily on Dupixent economics and the retinal franchise. A true moat must therefore be judged by whether the platform can replace maturing products with new large indications and medicines.

Who competes with the largest franchises?

Competition is product-specific. In retinal disease, Regeneron identifies Roche’s Vabysmo and Susvimo, Lucentis, Beovu, biosimilars, and compounded bevacizumab among alternatives. In immunology, Dupixent competes against therapies such as Lilly’s Ebglyss, AbbVie’s Rinvoq, and Galderma’s Nemluvio in relevant indications. Rivalry turns on efficacy, safety, dosing, physician familiarity, formulary access, net price, and indication breadth. Regeneron is strongest when clinical differentiation combines with convenience and reimbursement.

Regeneron enters its next investment cycle with a large net cash position and strong operating cash generation. At March 31, 2026, cash and marketable securities totaled $18.540 billion, compared with $1.986 billion of long-term debt. Total assets were $40.869 billion, total liabilities were $9.445 billion, and stockholders’ equity was $31.424 billion. The resulting net cash and marketable securities position was approximately $16.554 billion before other liabilities.

What does the annual baseline show?

FY2025 revenue was $14.343 billion, operating income was $3.578 billion, and net income was $4.505 billion. Operating cash flow reached $4.979 billion, while capital expenditures were $898 million, producing approximately $4.081 billion of free cash flow. R&D expense was $5.850 billion, or 40.8% of revenue. These figures from the FY2025 Form 10-K show a company that can fund a research budget comparable to the annual revenue of a sizable biotechnology peer while still producing substantial free cash flow.

How does Regeneron allocate capital?

Regeneron combines broad institutional ownership with a dual-class voting structure. Common stock has one vote per share; Class A stock has ten votes per share and can be converted into common stock. This gives founders and insiders more voting influence than their economic ownership alone would suggest. The institutional rows below reproduce the proxy’s cited Schedule 13G positions rather than live July 2026 holdings. According to the 2026 proxy statement, Leonard Schleifer beneficially owned 1,725,565 Class A shares, equal to 95.0% of that class, and 2,910,233 common-equivalent shares, equal to 2.8% of the common-equivalent total as of April 14, 2026.

Why does the dual-class structure matter?

Founder control can protect long-duration R&D from short-term pressure, but it can also reduce common-shareholder influence over strategy, succession, and capital allocation. Christine Poon serves as lead independent director, while Schleifer and Yancopoulos serve as co-chairs, preserving founder leadership at the board level.

Regeneron can expand through new indications, improved formulations, and new therapeutic areas. Dupixent can continue adding diseases and younger patient populations; EYLEA HD can convert more retinal patients to longer dosing intervals; Libtayo can broaden its oncology role; and late-stage programs can create new franchises. Its cash position limits reliance on external financing.

What are the most material constraints?

Customer concentration adds another operational risk. In Q1 2026, two customers represented 45% and 30% of gross product revenue, respectively. This reflects pharmaceutical distribution, not end-patient concentration, but wholesaler disruption or inventory changes can affect sales timing and working capital.

What is the newest disclosed item to watch?

A Form 8-K filed July 6, 2026 disclosed a preliminary expectation of approximately $127 million of acquired IPR&D expense for Q2 2026, with an estimated impact of about $1.00 on both GAAP and non-GAAP diluted EPS. The quarter had not been finalized, so this should be treated as a preliminary expense signal rather than a complete earnings result. It illustrates why quarterly biotechnology earnings can be volatile even when core product trends are stable.

Regeneron cannot be valued with a simple revenue multiple. The company combines mature cash-generating franchises, rapidly growing collaboration economics, declining legacy product sales, a large net cash balance, heavy R&D, and a broad pipeline with uncertain outcomes. A discounted cash flow model should separate drivers with different duration and risk.

Which variables have the greatest impact on intrinsic value?

Terminal value is especially sensitive to patent and exclusivity assumptions. If a model extends current product economics too long, it overstates durability; if it ignores lifecycle management and pipeline replacement, it understates the platform. Scenario analysis is therefore more appropriate than a single smooth forecast. A base case can use existing products and likely indication expansions, an upside case can add successful late-stage launches, and a downside case can accelerate erosion or assume weaker pipeline conversion.

Regeneron is important because it has converted a reusable discovery platform into several globally significant medicines while retaining the balance sheet to keep investing. Dupixent provides the strongest current growth engine, EYLEA HD is attempting to defend a valuable retinal franchise through lifecycle innovation, Libtayo is improving diversification, and the pipeline creates multiple paths to future value. Its mission to bring new medicines to patients “over and over again” is financially relevant because repeatability is the central strategic claim.